genprowebdirectory
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2023
Verve Therapeutics
GEN Edge
At Chardan Conference, David Liu Foresees First Prime Editing Clinical Trial in 2024
Alex Philippidis
-
October 10, 2023
0
Drug Discovery
Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger
Alex Philippidis
-
August 7, 2023
0
Drug Discovery
FDA Places Clinical Hold on Verve’s Cardio Base Editing Therapy
Alex Philippidis
-
November 7, 2022
0
Drug Discovery
Verve Therapeutics Doses First Patient with In Vivo Base Editing Therapy
Alex Philippidis
-
July 13, 2022
0
Keynote
Settling the Score with Genetic Diseases
GEN Staff Writer
-
March 12, 2020
0
Drug Discovery
Gene-Editing Cardiovascular Therapy Startup Licenses CRISPR Patents, Partners with Beam
Alex Philippidis
-
May 7, 2019
0
Scroll Up